98997-01-4

Usage

Uses

Used in Pharmaceutical Synthesis:
(1H-BENZOIMIDAZOL-2-YLMETHYL)-METHYL-AMINE is used as a building block for the synthesis of pharmaceuticals due to its unique structural features that can be incorporated into the development of new drugs.
Used in Agrochemical Synthesis:
In the agrochemical industry, (1H-BENZOIMIDAZOL-2-YLMETHYL)-METHYL-AMINE is used as a key component in the creation of various agrochemicals, contributing to the development of effective and innovative products for agricultural applications.
Used in Medicinal Chemistry and Drug Discovery:
(1H-BENZOIMIDAZOL-2-YLMETHYL)-METHYL-AMINE is utilized as a structural element in medicinal chemistry for the design and discovery of new drugs, taking advantage of its unique properties to target specific biological pathways or mechanisms.
Used in Organic Compound Synthesis:
(1H-BENZOIMIDAZOL-2-YLMETHYL)-METHYL-AMINE is also used as a fundamental component in the synthesis of a wide range of organic compounds, expanding its applications across various chemical and industrial sectors.

InChI:InChI=1/C9H11N3/c1-10-6-9-11-7-4-2-3-5-8(7)12-9/h2-5,10H,6H2,1H3,(H,11,12)

Upstream product

• 4857-04-9 2-chloromethyl-1H-benzimidazole 
• 74-89-5 methylamine 
• 163798-87-6 1-Boc-2-chloromethylbenzimidazole 
• 615-28-1 o-phenylenediamine dihydrochloride 
• 92809-96-6 2-(methylamino)methylbenzimidazole dihydrochloride 
• 593-51-1 methylamine hydrochloride 
• 95-54-5 1,2-diamino-benzene 

Downstream Products

• 136726-98-2 N-<4-<3-<(1H-benzimidazol-2-yl-methyl)methylamino>-2-hydroxypropoxy>phenyl>methanesulfonamide 
• 1031141-15-7 [5-(1H-benzimidazol-2-yl)-1-methyl-1H-pyrrol-3-yl](2-hydroxyphenyl)methanone 
• 1398498-98-0 N-methyl-1-{1-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]-1H-benzimidazol-2-yl}methanamine 
• 1398498-99-1 N-methyl-1-(1-{[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-benzimidazol-2-yl)methanamine 
• 1398499-00-7 1-(1-{[5-(4-ethylphenyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-benzimidazol-2-yl)-N-methylmethanamine 
• 1398499-01-8 N-methyl-1-(1-{[5-(4-propylphenyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-benzimidazol-2-yl)methanamine 
• 1398499-02-9 1-(1-((5-(4-butylphenyl)-1,3,4-oxadiazol-2-yl)methyl)-1H-benzimidazol-2-yl)-N-methylmethanamine 
• 1398499-10-9 2-{2-[(methylamino)methyl]-1H-benzimidazol-1-yl}-N'-[(E)-phenylmethylidene]acetohydrazide 
• 1398499-11-0 2-{2-[(methylamino)methyl]-1H-benzimidazol-1-yl}-N'-[(E)-(4-methylphenyl)methylidene]acetohydrazide 
• 1398499-12-1 N'-[(E)-(4-ethylphenyl)methylidene]-2-{2-[(methylamino)methyl]-1H-benzimidazol-1-yl}acetohydrazide 
• 1398499-13-2 N'-[(E)-(4-propylphenyl)methylidene]-2-{2-[(methylamino)methyl]-1H-benzimidazol-1-yl}acetohydrazide 
• 1398499-14-3 N'-[(E)-(4-butylphenyl)methylidene]-2-{2-[(methylamino)methyl]-1H-benzimidazol-1-yl}acetohydrazide 
• 1354972-20-5 1-(((1H-benzo[d]imidazol-2-yl)methyl)(methyl)amino)-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol 

Relevant academic research and scientific papers

Multi-substituted amine compound and its preparation and use (by machine translation)

The invention belongs to the field of medical technology, in particular, the present invention provides the following formula I shown multi-substituted amine compound or its isomer or its pharmaceutically acceptable salt, ester, prodrug or hydrate, its pharmaceutical composition, preparation method thereof and its use in the preparation of medicine for treating aids in use. The compound or pharmaceutical composition containing the compound can be used as an inhibitor for inhibiting HIV integrase with LEDGF/p75 between protein - protein interaction and HIV integrase dimerization, then can be used for the treatment of aids. . (by machine translation)

Some novel oxadiazolyl/azetidinyl benzimidazole derivatives: Synthesis and in vitro biological evaluation

In a wide search program for new and efficient antimicrobial agents, a series of oxadiazole/azetidinone-incorporated benzimidazoles have been synthesized and evaluated against different Gram-positive and Gram-negative bacteria. Derivatives having long alkyl chain on the oxadiazole/azetidinone moiety with three or more carbon atoms have shown less antibacterial activity.

BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS

The present invention provides compounds having formula (I) wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d are nitrogen atoms; Y and Y' each independently represents 1-4 optional substituents selected from alkyl, alkoxy, halo, -CF3, and -C(O)OH; R, R, R and R are H or specified substituents; R, R, R, R, R, R, R and R are independently selected from H or C1-C3 alkyl; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. Also provided are methods of using these compounds for treating vitronectin-mediated disorders, e.g., cancer, retinopathy, artherosclerosis, vascular restenosis, and osteoporosis.

Benzimidazole compounds that are vitronectin receptor antagonists

The present invention provides compounds having the formula wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d

Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity

Vitronectin receptor antagonists having the formula: STR1 which are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporsis.

Symmetry-Based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylhexane-3,4-diol

The structure-activity relationships in two series of novel, symmetry-based inhibitors of HIV protease, the enzyme responsible for maturation of the human immunodeficiency virus, are described.Beginning with lead compounds 3-6, the effect of adding polar, heterocyclic end groups to one or both ends of the symmetric or pseudosymmetric inhibitors was probed.Aqueous solubility was enhanced >1000-fold while maintaining potent inhibition of purified HIV-1 protease and anti-HIV activity in vitro.Pharmacokinetic studies in rats indicated a substantial difference in the absorption properties of mono-ol-based and diol-based inhibitors.The oral bioavailability of inhibitor 19 in rats was 19percent; however, the Cmax obtained failed to exceed the anti-HIV EC50 in vitro.Substantial plasma levels of potent inhibitors of the diol class were not obtained after oral administration in rats; however, the optimal combination of aqueous solubility and in vitro antiviral activity of several inhibitors support their potential use in intravenous therapy.

N-quinolinyl alkyl-substituted 1-aryloxy-2-propanolamine and propylamine derivatives possessing class III antiarrhythmic activity

This invention relates to N-heteroalkyl-substituted 1-aryloxy-2-propanolamine and propylamine derivatives possessing anti-arrhythmic activity, to pharmaceutical compositions and to methods for production thereof.

Substituted benzimidazole derivatives possessing Class III antiarrhythmic activity

This invention relates to N-heteroalkyl-substituted 1-aryloxy-2-propanolamine and proplyamine derivatives possessing anti-arrhythmic activity, to pharmaceutical compositions and to method for production thereof.

Synthesis and Selective Class III Antiarrhythmic Activity of Novel N-Heteroaralkyl-Substituted 1-(Aryloxy)-2-propanolamine and Related Propylamine Derivatives

The synthesis and biological evaluation of a series of novel 1-(aryloxy)-2-propanolamines and several related deshydroxy analogues are described.Compounds 4-29 were prepared and investigated for their class III electrophysiological activity in isolated canine Purkinje fibers and in anesthetized open-chest dogs.None of these compounds showed any class I activity.On the basis of the in vitro data, structure-activity relationships for the series are discussed.Two compounds, N-propoxy>phenyl>methanesulfonamide (12, WAY-123,223) and N-phenoxy>propyl>amino>methyl>-6-quinolinyl>methanesulfonamide (24, WAY-125,971) were identified and characterized as potent and specific class III antiarrhythmic agents in vitro and in vivo.Compound 12 was found to be orally bioavailable, to produce large increases of ventricular fibrillation threshold (VFT), and, in some instances, to restore sinus rhythm from ventricular fibrillation in anesthetized open-chest dogs at a dose of 5 mg/kg (iv).The enantiomers of 12 (i.e., 13 and 14) were synthesized and were found to exhibit similar electrophysiological effects in the Purkinje fiber screen.Compound 24, a propylamine analogue with potency and efficacy comparable to those of UK-68798 (2) and E-4031 (3), was studied in voltage-clamp experiments (isolated cat myocytes) and was found to be a potent and specific blocker of the delayed rectifier potassium current (IK).